Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 18, 1930


Author Affiliations

Sandoz Chemical Works, Inc.

JAMA. 1930;95(16):1195. doi:10.1001/jama.1930.02720160055027

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:  —We have seen the letter of Mr. Walter R. Fletcher of the British Medical Research Council concerning Gynergen (The Journal, September 6, p. 746).The statement objected to is found in a booklet issued by us early in 1928. It was based on evidence then in our files in New York which evidence, indeed, remained the only one we had up to the time we saw the letter of the British Research Council: namely, passages in the Pharmaceutical Journal of February 20, 1926: "It will be assumed that the therapeutically active substance is the specific alkaloid, ergotamine.... As standard, a sample of ergotamine tartrate is available prepared by the Sandoz Chemical Works.... After consultation with the Director of the Department of Biological Standards, Medical Research Council, it has been decided to approve as good samples of ergot, those containing not less than 1 mg. per gram of

First Page Preview View Large
First page PDF preview
First page PDF preview